MagicMed Industries Inc.

Private Company

Company Logo

Company Overview

MagicMed Industries intends to partner with pharmaceutical and other companies to develop psychedelic-derived medicinal and licit consumer goods products.

The company's molecular derivatives library, the Psybrary™, is anticipated to be an essential building block from which industry can develop new patented products. The initial focus of the Psybrary™ is on psilocybin, which is expected to be opportunistically expanded to other psychedelics like MDMA, ketamine, ibogaine, mescaline, and ayahuasca.

Management Team


Dr. Joseph Tucker
CEO

Dr. Jillian Hagel
COO

Dr. PEter Facchini
CSO

Sign Up for Alerts

Receive an email alert every time a company announces a merger, capital raise or files for an IPO.